DHL Group to Invest €2B by 2030 in Global Health Logistics

DHL Group has unveiled a major €2 billion investment plan over the next five years. The investment aims to strengthen its logistics services for the life sciences and healthcare sector. This move supports the Group’s “Strategy 2030” and reflects its goal to help healthcare companies grow, innovate, and serve patients more efficiently across the globe.

The investment will enhance DHL’s infrastructure, cold chain capacity, and digital systems. It aims to create faster, more resilient, and patient-focused logistics solutions. Half of the funding will support developments in the Americas, with 25% each allocated to the Asia Pacific and EMEA regions.

DHL plans to upgrade every logistics touchpoint—from storage and fulfillment to global shipping and last-mile delivery. The company will set up new GDP-certified Pharma Hubs for multi-temperature shipping and expand its temperature-controlled vehicle fleet. It will also improve packaging solutions to support safe and sustainable deliveries.

With growing demand in clinical trials, biopharma, and advanced therapies like cell and gene treatments, DHL is investing in specialized cooling infrastructure to handle ultra-low temperature requirements. The Group will also roll out advanced IT systems to provide real-time visibility and ensure regulatory compliance and product integrity.

Under the new sector brand DHL Health Logistics, the company will unify its expertise in life sciences and healthcare. This will offer clients a seamless end-to-end service, simplifying the management of complex global supply chains. The new structure is tailored for pharmaceutical, biopharma, and medical customers needing agile and integrated logistics.

“Our investment reflects our customers’ mission: to deliver life-saving products to those in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building smart, integrated logistics solutions that are as reliable as the medicines our clients produce. Our goal is to ensure every patient gets the right treatment at the right time.”

In 2024, DHL Group generated over €5 billion in revenue from life sciences and healthcare. It expects to double that figure by 2030. The company currently operates nearly 600 healthcare logistics sites in almost 130 countries, covering over 2.5 million square meters of temperature-controlled warehouse space.

Also Read: DHL Group Acquires CRYOPDP to Boost Health Logistics Division.

To support this expansion, DHL has also acquired CRYOPDP, a specialty courier focused on clinical trials, biopharma, and advanced therapies. This acquisition strengthens DHL’s Pharma Specialized Network and expands its reach in critical healthcare logistics segments.

Through this bold investment, DHL is deepening its commitment to healthcare logistics and advancing its mission to support global patient care.